Crescent Biopharma, Inc.
NASDAQ:CBIOBiotechnology
-$0.49 today
- Market cap
- $482.30M
- Beta
- 1.15
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$5.33
Volume 0.33M
Average 0.28M
CBIO Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Crescent Biopharma, Inc.NASDAQ: CBIO
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 5346.9% from a year ago
Total equity stood at $183.85M at the end of Q1 FY2026, up 5346.9% from a year earlier and down 9.4% from the prior quarter. Over 3 fiscal years it compounded at +67.8% a year.
Context
- Total equity amounted to 92.3% of total assets at the end of Q1 FY2026, up 36.0 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +5346.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 203.01M USD
- Year-over-year change
- +1411.5%
- 4-year CAGR
- +25.6%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 203.01M | +1411.5% |
| FY2024 | 2024-12-31 | (15.48M) | -140.3% |
| FY2023 | 2023-12-31 | 38.41M | -10.5% |
| FY2022 | 2022-12-31 | 42.93M | -47.4% |
| FY2021 | 2021-12-31 | 81.6M | — |
Total Equity vs competitors
How CBIO compares with its peers on the latest reported figures
- CBIO's Mar 2026 total equity of $183.85M is the 6th highest of the 10 companies compared; the peer median is $186.47M.
- Its year-over-year change of +5346.9% is the highest of 10, against a peer median of -15.5%.
- Total equity amounts to 92.3% of total assets for CBIO, versus a peer median of 88.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $649.47M | +8.5% | +17.4% | 90.0% | |
| Jun 2026 | $464M | -15.5% | -1.3% | 50.2% | |
| Mar 2026 | $319.94M | +1177.3% | — | 89.0% | |
| Sep 2026 | $258.25M | -19.3% | -18.3% | 22.0% | |
| Mar 2026 | $186.47M | +69.1% | +2.7% | 90.9% | |
| Mar 2026 | $183.85M | +5346.9% | +67.8% | 92.3% | |
| Mar 2026 | $95.35M | +67.0% | +9.8% | 65.4% | |
| Mar 2026 | $52.2M | -42.6% | +20.3% | 88.7% | |
NBPNovaBridge Biosciences | Dec 2025 | $33.02M | -97.8% | -77.8% | 88.6% |
| Mar 2026 | $21.2M | -73.2% | -26.8% | 9.7% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CBIO) | $186.47M | -15.5% | +0.7% | 88.6% | |
Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 90.25M | 47.87M | 41.79M | 34.77M | 213.19M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.35K | 144.02K | 175.82K | 0 | 18M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 38K | 1.28M |
| Total Current Assets | 90.79M | 50.71M | 43.79M | 34.8M | 236.66M |
| Property, Plant & Equipment (Net) | 1.95M | 751.17K | 767.83K | 0 | 2.32M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 4.73M |
| Long-term Investments | 0 | 0 | 0 | 0 | 107K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.61M | 344.71K | 757.91K | 813K | (3.51M) |
| Total Non-current Assets | 3.56M | 1.1M | 1.53M | 813K | 3.64M |
| Total Assets | 94.35M | 51.81M | 45.32M | 35.62M | 240.29M |
| Account Payables | 2.11M | 970.19K | 868.12K | 107K | 10M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 4.16M |
| Other Current Liabilities | 2.5M | 2.97M | 2.96M | 76K | 16.36M |
| Total Current Liabilities | 11.82M | 8.88M | 6.84M | 9.61M | 36.07M |
| Long-term Debt | 0 | 0 | 0 | 37.48M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 4M | 0 |
| Total Non-current Liabilities | 918.61K | 0 | 66.84K | 41.48M | 1.21M |
| Total Liabilities | 12.74M | 8.88M | 6.9M | 51.1M | 37.28M |
| Common Stock | 52.31K | 54.38K | 64.39K | 1K | 28K |
| Retained Earnings | (372.9M) | (419.59M) | (456.49M) | (17.87M) | (171.81M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 81.6M | 42.93M | 38.41M | (15.48M) | 203.01M |
| Total Debt | 1.92M | 918.56K | 808.4K | 37.48M | 1.64M |
| Net Debt | (88.33M) | (46.95M) | (40.98M) | 2.72M | (211.55M) |
Crescent Biopharma, Inc.
NASDAQ:CBIO
Intrinsic Alpha fair value
Locked
Current Price
$12.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.